Using outcomes identified as sensitive to AD progression, we estimated possessing an APOE ε4 allele accounted for approximately 8% of variance in scores, and modest sample sizes would be sufficient to detect a significant treatment effect to delay cognitive decline in an RCT. This evidence concerns the gene APOE and Mental deterioration.